Skip Navigation LinksHome > Annual Meeting > Learn > Joint Sessions

Joint Sessions

AABB has partnered with related professional organizations on the following joint sessions. We would like to thank these organizations for helping us to provide attendees with unique, high-quality sessions.

The Effect of Apheresis on Medications: A Review
Regenerative Medicine Therapies for the Clinic
Developments in Transfusion Associated Circulatory Overload (TACO)
Challenges and Opportunities in HCT Donation

Register

The Effect of Apheresis on Medications: A Review

AABB/ASFA
Sunday, October 14 | 8:30 am – 10:00 am

Category: Therapeutic Apheresis
Keywords: Evidence Based Medical Practices | Patient Safety | Professional Development | Therapeutic Apheresis

The term apheresis is a Greek term and it means “to remove forcibly.” It encompasses many treatment modalities including therapeutic plasma exchange, red cell exchange, lipid apheresis, extracorporeal photopheresis and mononuclear cell collections. While most apheresis practitioners are knowledgeable on the various aspects of apheresis, the effect of apheresis on the pharmacokinetics of different medications is less known. This session will focus on the removal of medications by different apheresis modalities, pharmacokinetics affected by apheresis, and strategies for drug management.

At the completion of this session, participants should be able to:

  • Review apheresis modalities and its physiology as it pertains to medication interaction and clearance.
  • Describe the effect of therapeutic apheresis on the pharmacokinetics of different drugs.
  • Discuss strategies for appropriate drug management.
  • Review anticoagulants and their effects on apheresis treatment.

Program Chair:
Dr. Tina S. Ipe

Houston Methodist Hospital
Houston, TX

Speakers:
Dr. Rami B. Ibrahim, PharmD

Michigan State University College of Osteopathic | Wayne State University School of Medicine
East Lansing, MI

Dr. Tina S. Ipe
Houston Methodist Hospital
Houston, TX

Dr. Sara Shunkwiler, MD
University of Nebraska Medical Center
Omaha, NE

Back to top


Regenerative Medicine Therapies for the Clinic

AABB/TERMIS-AM
Sunday, October 14 | 10:30 am - 12:00 pm

Regenerative medicine focuses on the development of new approaches to repairing cells, tissues and organs for clinical applications. This session will provide a better understanding of the translational processes that facilitate safe delivery of clinical therapies to patients. The speakers will highlight technologies that are being applied in patients as well as those that are currently in development.

At the completion of this session, participants should be able to:

  • Discuss basic principles of cell-based therapies.
  • Discuss the practical aspects associated with clinical translation.
  • Discuss ongoing/planned applications of regenerative medicine therapy.

Program Chair:
James J. Yoo, MD, PhD
Wake Forest Institute for Regenerative Medicine
Winston-Salem, NC

Speakers:
Jennifer H. Elisseeff, PhD
Johns Hopkins University
Baltimore, MD

John D. Jackson, PhD
Wake Forest Institute for Regenerative Medicine
Winston-Salem, NC

Back to top


Developments in Transfusion Associated Circulatory Overload (TACO)

AABB/ISBT
Monday, October 15 | 2:00 pm – 3:30 pm

Category: Transfusion Service
Keywords: Evidence Based Medical Practices | Recipient/Patient Hemovigilance - Noninfectious Adverse Events (Transfusion Reactions) | Transfusion Medicine Clinical Practices

Transfusion associated circulatory overload (TACO) is now recognized to be one of the most frequent causes of serious transfusion-related morbidity and mortality and it can be mitigated or prevented by relatively simple measures. This is the first of two sessions will give an overview of TACO and provide intervention and mitigation strategies while identifying critical gaps in our understanding of the syndrome. This session will focus on the incidence of TACO, current knowledge of its pathophysiology, and recognizing TACO in vulnerable patients. Participants will become better acquainted with the early warning signs of potential TACO and be better able to support awareness of TACO and use of preventive practices among colleagues in their institutions.

An international joint working group including members of the ISBT haemovigilance working party, the International Haemovigilance Network, and AABB has revised the reporting criteria for TACO. The revised definition will contribute to the comparability of data from different hemovigilance systems and countries. More importantly, however, the group hopes to increase awareness of TACO’s contribution to patient morbidity and mortality and foster more timely and accurate TACO diagnoses to prevent its occurrence.

At the completion of this session, participants should be able to:

  • Explain why Transfusion Associated Circulatory Overload (TACO) is important.
  • Describe the revised international hemovigilance reporting criteria for TACO.
  • Discuss the pathophysiology of TACO. Is it purely a hydrostatic problem?
  • Recognize TACO warning signs, HOT TACO, and full-blown TACO.

Program Chair:
Dr. Kevin J. Land, MD
UT Health Science Center San Antonio
San Antonio TX

Blood Systems
Tempe AZ   

Speakers:
Dr. Chester Andrzejewski, Jr., PhD, MD, FCAP

Baystate Health / Baystate Medical Center
Springfield, MA

Dr. Johanna C Wiersum-Osselton
Transfusion Reactions in Patients (TRIP) Dutch National Hemovigilance Office
Leiden, Netherlands

Back to top


Challenges and Opportunities in HCT Donation

AABB/NMDP
Tuesday, October 16 | 11:00 am - 12:30 pm

Category: Education
Keywords: Training

The assessment of HCT donors presents unique clinical challenges. Medical judgment also offers opportunities to safely allow donation when they are the best match for a particular patient. This session will use a case study format to provide an overview of the clinical evaluation of HCT donors to determine if they are suitable for donation. As part of the session, we will compare the evaluation of HCT and blood donors. We will explore how improvements in the availability of donors and their time of evaluation may impact transplant outcomes.

The clinical development of new cellular therapy products is growing rapidly. This session will examine the unique ethical and clinical challenges in evaluating donors to support these novel therapies.

At the completion of this session, participants should be able to:

  • Compare differences in the medical evaluation of blood and HCT donors.
  • Recognize how medical judgment is incorporated in the assessment of HCT donors presenting with complex case histories.
  • Describe how donor availability and timeliness of donor evaluation might impact clinical outcomes of transplantation.
  • Summarize new developments in cellular therapies and the clinical and ethical questions they raise.

Program Chair:
John P. Miller, MD, PhD
National Marrow Donor Program
Minneapolis, MN  

Speakers:
John P. Miller, MD, PhD
National Marrow Donor Program
Minneapolis, MN

Sheila Moran, RN BAN
National Marrow Donor Program
Minneapolis, MN

Back to top